Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors (Q27851450)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q60394812)
(Q60320900)
(Q66370727)
(Q66370888)
(Q66385413)
(Q87038533)
(Q114427955)
(P304) 4839-42
(P407) (Q1860)
(P433) 13
(P478) 112
(P577) Monday, December 15, 2008
(P921) (Q7141)
(Q729735)
(Q181600)
(Q29496)
(P1433) (Q885070)
(P1476) "Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors" (language: en)
(P2093) Dan Jones
(P2860) (Q24681743)
(Q28246204)
(Q28246193)
(Q28243392)
(Q29618788)
(Q33844041)
(Q34567629)
(Q40425892)
(Q33927591)
(Q40595438)
(Q38361603)
(Q42742043)
(Q43899710)
(Q46915157)
(Q56995709)
(Q56999804)
(Q44353700)
(Q44267685)
(Q80317123)
(Q81039035)
(Q83154106)
(Q79950167)
other details
description scientific article

External Links